Search Results

You are looking at 191 - 200 of 377 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Vaccinations for Patients With Cancer and Cancer Survivors

Presented by: Maria Alma Rodriguez

“While under active treatment, patients with cancer are vulnerable to infection, as chemotherapy, radiation therapy, and immune-altering therapies can lead to neutropenia, lymphopenia, and altered immune competence,” commented Maria Alma Rodriguez

Full access

New Settings for Immune Checkpoint Inhibitors in Urothelial Cancer

Presented by: Arlene O. Siefker-Radtke

properties as well, according to Dr. Siefker-Radtke. She also stated that neutropenia and lymphopenia are frequently reported with agents such as gemcitabine, which could impact the ability to induce an immune response. A phase II study showed evidence of

Full access

NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Deborah M. Stephens

leading to treatment discontinuation with zanubrutinib. One notable side effect of zanubrutinib was a tendency to cause more neutropenia, although this did not correlate to neutropenic fever or higher rates of grade 3 infections. “The findings of these 2

Full access

Targeted Therapy for Metastatic Non–Small Cell Lung Cancer

Presented by: Gregory J. Riely

compared with docetaxel,” he said, especially with less neutropenia and alopecia. The NCCN Guidelines recommend sotorasib or adagrasib as second-line therapy options in patients with KRAS G12C mutation–positive metastatic NSCLC. 4 “So, in the second

Full access

Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis

baseline hematologic abnormalities (ie, neutropenia) can be exacerbated by interferon (IFN) alfa and ribavirin-containing HCV therapy. 10 Other reasons for excluding these patients is the potential for HCV to affect the toxicity and/or efficacy of the

Full access

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman

neutropenia, myelosuppression was generally modest and reversible, potentially reflecting the minimal expression of IL3R on normal myeloid progenitors. Many patients experienced transaminitis without hyperbilirubinemia, with onset typically 5 to 10 days

Full access

Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Dong Ding, Huabin Hu, Shuosha Li, Youwen Zhu, Yin Shi, Mengting Liao, Jin Liu, Xu Tian, Aiting Liu, and Jin Huang

durvalumab. Other considerable influential parameters were risk of neutropenia in chemotherapy group, risk of neutropenia in durvalumab group, and utility of PD. Figure 1. Tornado diagram for one-way sensitivity analysis. Abbreviations: ICER

Full access

Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA >2 m 2 , age ≥65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been

Full access

Changes in Prescribing Patterns in Stage III Colon Cancer

Fang-Shu Ou, Daniel J. Walden, Joseph J. Larson, Sandra Kang, Cassia R. Griswold, Benjamin E. Ueberroth, Bhamini Patel, Amber Draper, Puneet Raman, Olatunji B. Alese, Mohamad B. Sonbol, Tanios S. Bekaii-Saab, Christina S. Wu, and Daniel H. Ahn

(trAEs), including neutropenia, thrombocytopenia, and permanent peripheral neuropathy, that may limit the clinical benefits of FOLFOX chemotherapy. 5 Given the need to balance survival outcomes with toxicity, the IDEA collaboration aimed to evaluate the

Full access

Resurrection of PARP Inhibitors in Breast Cancer

Tomas G. Lyons and Mark E. Robson

anemia (39.2% vs 4.8%) and thrombocytopenia (14.7% vs 1.6%); however, grade 3 or 4 neutropenia was less frequent with talazoparib (20.9% vs 34.9%). Veliparib Veliparib has been evaluated as both a monotherapy and in combination with chemotherapy